SCHEMBL4725175

SCHEMBL4725175

Cc1ccc2nc(Cl)[nH]c(=O)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TUBB4A P04350 1/20 0.55
TUBB P07437 1/20 0.55
TUBA3C P0DPH7 1/20 0.55
TUBA1B P68363 1/20 0.55
TUBA4A P68366 1/20 0.55
TUBB4B P68371 1/20 0.55
TUBB3 Q13509 1/20 0.55
TUBB2A Q13885 1/20 0.55
TUBB8 Q3ZCM7 1/20 0.55
TUBA3E Q6PEY2 1/20 0.55
TUBA1A Q71U36 1/20 0.55
TUBA1C Q9BQE3 1/20 0.55
TUBB6 Q9BUF5 1/20 0.55
TUBB2B Q9BVA1 1/20 0.55
TUBB1 Q9H4B7 1/20 0.55
PARP1 P09874 3/20 0.51
LMNA P02545 3/20 0.50
TYMS P04818 1/20 0.48
KDM4E B2RXH2 4/20 0.47
MAPT P10636 3/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30062569 1.00 TUBB4A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL23333473 0.86 PARP1 (0.51) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3423481 0.82 KDM4E (0.59) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29535139 0.82 KDM4E (0.66) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL7263029 0.82 KDM4E (0.66) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3672857 0.79 TYMS (0.72) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL3424900 0.79 TUBB4A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL12693599 0.79 KDM4E (0.42) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL29850802 0.79 TYMS (0.72) TUBB4ATUBBTUBA3CTUBA1BTUBA4A
SCHEMBL14239552 0.79 TUBB4A (0.55) TUBB4ATUBBTUBA3CTUBA1BTUBA4A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12582661-B2 Synthesis and application of class of respiratory syncytial virus inhibitors Shanghai Ark Biopharmaceutical Co., Ltd. (CN) 2026-03-24 US disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
US-RE49481-E1 Compounds for the treatment and prophylaxis of respiratory syncytial virus disease HOFFMANN-LA ROCHE INC. (US) 2023-04-04 US disclosed
US-20230090060-A1 SYNTHESIS AND APPLICATION OF CLASS OF RESPIRATORY SYNCYTIAL VIRUS INHIBITORS Shanghai Ark Biopharmaceutical Co., Ltd. (CN) 2023-03-23 US disclosed
EP-4095136-A1 SYNTHESIS AND USE OF CLASS OF RESPIRATORY SYNCYTIAL VIRUS INHIBITORS Suzhou Ark Biopharmaceutical Co., Ltd (CN) 2022-11-30 EP disclosed
CN-115023423-A Synthesis and application of respiratory syncytial virus inhibitor 苏州爱科百发生物医药技术有限公司 2022-09-06 CN disclosed
WO-2021147947-A1 SYNTHESIS AND USE OF CLASS OF RESPIRATORY SYNCYTIAL VIRUS INHIBITORS 苏州爱科百发生物医药技术有限公司 2021-07-29 WO disclosed
WO-2021147947-A1 SYNTHESIS AND USE OF CLASS OF RESPIRATORY SYNCYTIAL VIRUS INHIBITORS 苏州爱科百发生物医药技术有限公司 2021-07-29 WO disclosed
CN-113149977-A Synthesis and application of respiratory syncytial virus inhibitor 苏州爱科百发生物医药技术有限公司 2021-07-23 CN disclosed
CN-105949203-A Octahydropyrrole[3, 4-c]pyrrole derivative and using method and application thereof 广东东阳光药业有限公司 2016-09-21 CN disclosed
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE HOFFMANN-LA ROCHE INC. 2013-08-01 US disclosed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 WO disclosed
WO-2013020993-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE F. HOFFMANN-LA ROCHE AG (CH) 2013-02-14 WO disclosed
WO-2008016666-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO disclosed
WO-2008016666-A2 CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS CYTOKINETICS, INCORPORATED (US) 2008-02-07 WO disclosed
US-5187167-A Antitumor agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1993-02-16 US disclosed
US-5081124-A Amino acid and polyamino acid derivatives, inhibitors of thymidylate synthetase IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1992-01-14 US disclosed
EP-0239362-B1 ANTI-TUMOR AGENTS IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-12-04 EP disclosed
US-4992550-A Thymidylate synthetase inhibitors IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1991-02-12 US disclosed
EP-0239362-A2 Anti-tumor agents IMPERIAL CHEMICAL INDUSTRIES PLC (GB) 1987-09-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130196974-A1 COMPOUNDS FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS DISEASE CFTR, H1-10, RECQL TUBB4A 2933/4885TUBB 3102/4885TUBA3C 2925/4885
US-20230090060-A1 SYNTHESIS AND APPLICATION OF CLASS OF RESPIRATORY SYNCYTIAL VIRUS INHIBITORS SI, FURIN, ACE TUBB4A 4775/4885TUBB 4617/4885TUBA3C 4589/4885
US-12582661-B2 Synthesis and application of class of respiratory syncytial virus inhibitors SNU13, TMPRSS11D, SPTBN1 TUBB4A 4611/4885TUBB 4288/4885TUBA3C 3450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.